Commentary

Propylthiouracil (PTU) Hepatoxicity in Children and Recommendations for Discontinuation of Use

Scott A. Rivkees1 and Donald R. Mattison2

1 Yale Pediatric Thyroid Center, Yale University School of Medicine, New Haven, CT 06520, USA
2 Obstetric and Pediatric Pharmacology Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD 20892, USA

Correspondence should be addressed to Scott A. Rivkees, scott.rivkees@yale.edu

Received 5 April 2009; Accepted 7 April 2009

Propylthiouracil (PTU) was introduced for clinical use in July 1947 for Graves’ disease (GD) treatment. Over the 60 years that this medication has been used, reports of PTU-related liver failure and death have accumulated. On October 28, 2008, an expert panel evaluated PTU drug safety in children at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). It is estimated that about 4000 pediatric patients per year with GD are being treated with antithyroid drugs (ATDs) in the United States, and up to 30% of pediatric patients with GD are being treated with PTU. The risk of severe PTU-induced liver failure is estimated as 1 in 2000–4000 children. The number of children developing reversible PTU-induced liver injury is estimated to be at least 1 in 200. Routine biochemical surveillance of liver function and hepatocellular integrity is not useful in identifying children who will develop liver failure. Children appear to be at higher risk for PTU-induced liver injury than adults. PTU should not be used as first line therapy for the treatment of GD in children. Current PTU use in children taking this medication should be stopped in favor of alternate therapies.

Copyright © 2009 S. A. Rivkees and D. R. Mattison. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

1. Propylthiouracil

Graves’ disease (GD) is the most common cause of hyperthyroidism and is treated with antithyroid drugs (ATDs), radioactive iodine, or surgery [1]. In the pediatric population, the ATDs propylthiouracil (PTU) and methimazole (MMI) are widely used as first line therapy, with many children treated with ATDs for extended periods [1].

Propylthiouracil (6-propyl-2-thiouracil), was introduced for clinical use in July 1947 and has played a seminal role in the treatment of hyperthyroidism [2, 3]. PTU acts by inhibiting the enzyme thyroperoxidase, which adds iodide to tyrosine residues on the thyroxine hormone precursor thyroglobuloiine [4]. PTU also inhibits the enzyme tertiiodothyronine 5’ deiodinase, which converts thyroxine (T4) to triiodothyronine (T3) [5].

Whereas countless individuals have benefited from PTU therapy, over the 60 years that this medication has been used, reports of PTU-related liver failure and death in children and adults have accumulated [6, 7]. These observations raise major concerns about the safety of this medication, especially in children.

2. Case Reports

Twenty nine cases of PTU-induced liver failure have been reported in individuals with ages ranging between 6 and 62 years [8–42]. Recovery from liver failure without transplant occurred in 18 individuals, transplantation occurred in 3 persons, and 9 deaths were reported. Of these cases, 14 were pediatric patients [8, 12, 14, 21, 22, 25, 26, 29, 31, 35, 37, 39, 41, 43] (Table 1). There were three deaths in PTU-treated pediatric patients. Five children who underwent liver transplantation have been reported.

In comparison with reports of PTU-induced hepatocellular necrosis, liver-related problems associated with MMI use are related to cholestasis, which has been reported in 20 adults [44–53]. MMI-related cholestasis is associated with high doses and older age [51]. There is one case report of MMI-related liver failure leading to death in a 43-year-old man with hyperthyroidism and hepatitis B [54]. The death of a 20-year-old woman treated with 90 mg/day of methimazole for eight months has been reported [26].

We are unaware of reports of MMI-related liver failure, liver transplants, or deaths in pediatric patients.
3. Adverse Event Reports

Data from 48 US Food and Drug Administration (FDA) reports and ATD-related adverse event (AE) reports in individuals <18 years of age from 1970 to 1997 were available as part of a previous analysis of pediatric GD treatment [55]. Thirty-four reports were related to PTU; 14 reports were related to MMI (Table 2).

PTU-related AEs included rashes, leukopenia, arthritis, vasculitis, liver injury, and death. PTU was associated with hospitalization in 18 children. Liver injury was reported in 18 patients. The time from onset of therapy until recognized liver injury was 1 to 23 months. Renal failure due to vasculitis was reported in three children taking PTU.

MMI-related AEs included rashes, urticaria, arthralgias, and vasculitis. There were no reports of liver or renal injury. MMI-related AEs were associated with hospitalization in three children. There were no reports of MMI-induced liver failure, liver transplants, or deaths.

4. Cohort Studies

Studies reporting outcomes of pediatric GD treated with PTU, in which AEs were discussed, were evaluated [56–62] (Table 3). These cohorts included more than 550 PTU-treated patients. AEs related to PTU use occurred in 15 to 35% of children, except for one report that described AEs in 1 of 63 patients.

Cohort studies describing AEs related to MMI are few. In a recent study of the MMI analog carbimazole, of 147 treated children, eight children developed rashes, and one child developed agranulocytosis [58].

5. Liver Transplantation Data

In 2004, drug-induced liver injury was reported to account for 15% of liver transplants in the Organ Procurement and Transplantation Network (OPTN) and United Network for Organ Sharing (UNOS) database [64]. Acetaminophen accounted for 50% of drug-related transplants, followed by isoniazid (17%) [64]. PTU was the third most common cause of drug-induced liver failure, accounting for 10% of drug-related transplants [64]. The age range of PTU-related transplant recipients was 6 to 69 years [64].

As of September 22, 2008, data from OPTN and UNOS reveal a total of 23 PTU-related liver transplants from 1990 to 2007. 30% of liver transplant recipients were pediatric patients (Table 4). No MMI-related liver transplants occurred over this period in either children or adults.

6. NICHD, OPPB Workshop

The above concerns about a PTU safety were relayed to the NICHD Obstetric and Pediatric Pharmacology Branch (OPPB) [7]. Under the umbrella of the Best Pharmaceuticals for Children Act (information on BPCA is available at: http://b pca.nichd.nih.gov/), a workshop was held at the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) on October 28, 2008 to evaluate PTU drug safety in children.

Workshop participants included members of the NIH and FDA and experts in thyroidology, pediatric endocrinology, hepatology, epidemiology, and adverse event surveillance. Speakers included Vicky Border-Hemphill, Pharm D (FDA), James Boyer, M.D. (Yale University), Wida Cerik, Ph.D. (United Network for Organ Sharing), David S. Cooper, M.D. (Johns Hopkins University School of Medicine), James Korelitz, Ph.D. (Westat Research), Scott A. Rivkees, M.D. (Yale University), John Senior, M.D. (FDA), Robert Squires Jr., M.D., (University of Pittsburgh), Joslyn Swann, Pharm D., (FDA), and Ana Szarfman, M.D. (FDA). Surendra Varma, M.D. represented the American Academy of Pediatrics (AAP).

The following ATD-related information was evaluated: published reports of AEs, FDA adverse event reports (AERs), prescribing practices, Pediatric Acute Liver Failure network data, and OPTN UNOS liver transplantation data. Minutes of this meeting are currently available [7]. The following observations and estimates were made.

(1) The prevalence of GD in children in the United States is about 1 in 10,000 children. About 4000 pediatric patients per year with GD are being treated with ATDs in the United States. In 2004, 40% of children with GD were treated with PTU. Over the past four years, the number of PTU prescriptions for children with GD has decreased by about 50%, and the number or prescriptions for MMI have increased by about 50%.

(2) The risk of PTU-induced liver failure leading to transplantation is about 1 in 2000–4000 children. (About 0.5 PTU-related liver transplants per year in children; ~1000 to 2000 children per year taking PTU.) Once PTU-induced liver failure occurs, it is rapidly progressive with a low chance of reversibility. The number of children developing PTU-induced liver injury that is reversible is estimated to be at least tenfold greater than the number of children who develop liver failure requiring transplantation.

(3) Routine biochemical surveillance of liver function and hepatocellular integrity (serum bilirubin, alkaline phosphatase and transaminase levels) will not be useful in identifying children who will develop PTU-induced liver failure.

(4) Children are at higher risk for PTU-induced liver than adults.

(5) PTU-induced liver injury is an important concern for the adult population. The number of adults with GD is at least fourfold higher than the number of children with GD. The proportion of adult patients prescribed PTU for GD is currently greater than the proportion of pediatric patients prescribed PTU. Whereas the proportion of children prescribed PTU for GD has decreased over the past four years, PTU prescribing practices have remained steady in the adult population.
Table 1: Case reports of propylthiouracil-related liver injury in pediatric patients.

| Authors, year       | Age (years) | Gender | Daily dose (mg) | Duration of PTU | Liver abnormality      | Outcome        |
|---------------------|-------------|--------|-----------------|-----------------|------------------------|----------------|
| Moore, 1946 [8]     | 12          | F      | 300             | 0.5 months      | Liver injury           | Recovery       |
| Parker, 1975 [12]   | 9           | F      | 300             | 2 months        | Portal inflammation    | Recovery       |
| Reddy, 1979 [14]    | 10          | F      | 300             | 1.2 months      | Hepatitis              | Recovery       |
| Bloch et al., 1985 [21] | 12          | M      | 450             | 2 months        | Hepatitis              | Recovery       |
| Garty et al., 1985 [22] | 12          | F      | 300             | 1 month         | Hepatitis              | Recovery       |
| Limaye and Ruffolo, 1987 [24] | 6           | F      | 300             | 4 months        | Hepatitis              | Recovery       |
| Jonas and Eidson, 1988 [25] | 13          | F      | 300             | 7 months        | Massive necrosis       | Death          |
| Baker et al., 1989 [26] | 9           | F      | 300             | 3 months        | Hepatitis              | Recovery       |
| Kirkland, 1990 [29] | 9           | F      | 300             | 4 months        | Liver failure          | Transplant/Recovery |
| Levy, 1993 [31]     | 11          | F      | 300             | 14 months       | Liver failure          | Death          |
| Deidiker and deMello, 1996 [41] | 13          | F      | 250             | 4 months        | Liver failure          | Transplant/Death |
| Williams et al., 1997 [43] | 14          | F      | 450             | 4 months        | Liver failure          | Transplant/Recovery |
| Testa et al., 2003 [35] | 17          | F      | 450             | 6 months        | Liver failure          | Transplant/Recovery |
| Sipe et al., 2006 [37] | 7           | F      | 300             | 9 months        | Liver failure          | Transplant/Recovery |

Table 2: Adverse events reported to the FDA from 1970 to 1997 in individuals ≤ 18 years of age.

| Adverse event                  | Propylthiouracil | Methimazole |
|--------------------------------|------------------|-------------|
| Total number                    | 34               | 14          |
| Hospitalizations                | 18               | 3           |
| Deaths                          | 2                | 0           |
| Liver injury: mild              | 1                | 0           |
| Liver injury: serious           | 13               | 0           |
| Liver transplantation           | 2                | 0           |
| Liver injury-related death      | 2                | 0           |
| Agranulocytosis                 | 1                | 1           |
| Leukopenia                      | 3                | 1           |
| Thrombocytopenia                | 1                | 0           |
| Renal injury                    | 3                | 0           |
| Vasculitis                      | 3                | 1           |
| Arthritis                       | 1                | 2           |
| Arthralgia                      | 1                | 1           |
| Rash/urticaria                  | 5                | 9           |

(6) MMI is not associated with a risk liver failure in the pediatric population.

(7) PTU is associated with much higher risk of antineutrophil cytoplasmic antibody (ANCA) development and vasculitis than MMI.

(8) PTU and MMI have comparable rates of agranulocytosis (0.3% in adults). The risk of agranulocytosis is dose-dependent with MMI but not with PTU. The risk of agranulocytosis is very low with low doses of MMI.

(9) MMI use during pregnancy is associated with an increased risk of birth defects (aplasia cutis, choanal atresia, esophageal atresia, tracheoesophageal fistulas, and athelia). PTU use during pregnancy is not associated with birth defects. Women should be informed of the potential risks of PTU-hepatotoxity and risks of MMI-associated fetal minor malformations when considering ATD use during pregnancy.

(10) Even though there was more MMI than PTU use in children over periods when PTU-induced liver failure has been reported, there are no reports of liver failure or liver transplants associated with MMI use in children. There are also fewer and less serious AERs in the FDA database for MMI than PTU.

(11) There is no good plan for managing hepatotoxicity risk in a PTU-treated patient, other than not using the drug.

7. The Need to Consider Alternatives to PTU

Considering the above, we believe that PTU should never be used as first line treatment in children with GD [6, 65]. We also believe that it is reasonable and prudent to discontinue PTU use in the children taking this medication for the treatment of GD.

In the United States and many countries, MMI is available and should be considered as the alternative ATD to PTU. In several countries, carbimazole [66], which is converted to MMI, is available and should be considered as the alternative ATD to PTU.

When using MMI in the treatment of GD, practitioners should consider the following. In comparison with PTU, MMI dosing is more convenient and associated with better compliance [67], as the tablets are small (5 or 10 mg), and
### Table 3: Pediatric cohort studies of propylthiouracil-related adverse events.

| Authors, year       | N    | AE (n) | % AE | Adverse events                                                                 |
|---------------------|------|--------|------|-------------------------------------------------------------------------------|
| Hamburger, 1985 [57]| 182  | 31     | 17%  | 11 Cutaneous 1 Cutaneous and neutropenia 1 Cutaneous and rheumatological 1 Cutaneous and hepatic 1 Cutaneous and pharyngitis 4 Neutropenia 2 Hepatic 1 Rheumatological 2 Nausea 5 Multiple infections without neutropenia 1 Unspecified |
| Lippe et al., 1987 [59]| 63  | 1      | 1.5% | 1 Arthritic reaction |
| Ward et al., 1999 [62]| 33  | 8      | 24%  | Rash, arthralgia, nausea, vomiting |
| Lazar et al., 2000 [63]| 28  | 14     | 35%  | 2 Major; agranulocytosis; toxic hepatitis 12 Minor |
| Somnueke et al., 2007 [61]| 32  | 2      | 6%   | ANCA; nephritis Rash, arthralgia |
| Glaser and Styne, 2008 [56]| 70  | 11     | 16%  | 1 Rash 2 Rash and arthralgia 1 Arthritis with purpura 1 Arthritis with purpura, hematuria 3 Elevated liver function tests 2 Marked elevated liver function tests 2 Neutropenia |
| Ma et al., 2008 [60]| 40  | 8      | 20%  | 6 Serious |
|                     | 48  | 7      | 14.6%| NA |

MMI can be given once daily [4]. The MMI dose range is typically used by our center is 0.1 to 0.3 mg/kg per day, with doses given once daily. Because MMI comes in 5 and 10 mg tablets, which are small and difficult to cut precisely, we commonly prescribe the following doses: infants, 1.25 mg per day; 1 to 5 years, 2.5 to 5.0 mg per day; 5 to 10 years, 5 to 10 mg per day; 10 to 18 years, 10 to 20 mg a day. With severe hyperthyroidism (free T4 > 4 ng/dL), doses 50% to 100% higher than above can be used.

Although MMI has a better overall safety profile than PTU, MMI is associated with minor adverse events that may affect up to 10% of children. MMI-related adverse events include allergic reactions, rashes, myalgias, and arthralgias. Agranulocytosis has been reported in about 0.3% of adult patients taking MMI or PTU [4, 68, 69]. Agranulocytosis is dose-dependent with MMI and rarely occurs at low doses [4, 68, 69]. When it develops, agranulocytosis develops over the first 100 days of therapy in 95% of individuals [4, 68, 69]. Thus, if a patient taking MMI feels ill for any reason, they should immediately discontinue their medication and contact their physician. Although side effects to MMI most commonly occur within the first 6 months of therapy, adverse events can occur with prolonged therapy. In our clinical practice, we find that 4% of children on MMI developed adverse events after 18 months of therapy.

The issue of how long ATDs should be used in children before considering either radioactive iodine or surgery warrants further study. Many practitioners will consider a trial of ATDs for up to two years and proceed to surgery or radioactive iodine if remission (i.e., euthyroid after cessation of ATDs) does not occur. Practitioners may also elect to continue antithyroid medications for longer as long as toxic reactions do not occur.

Properly administered, radioactive iodine is an acceptable and effective treatment for GD in the pediatric population [70]. The use of radioactive iodine in the pediatric population, though, is viewed as controversial by some [71].

The goal of contemporary 131I therapy for GD is hypothyroidism. Radioactive iodine should not be given to make patients euthyroid, as this will result in remaining partially-irradiated thyroid tissue, and it is recognized that there is an increase risk of thyroid neoplasm when children receive low doses of 131I for GD [72, 73].

When used, >150 uCi of 131I per gm of thyroid tissue should be given to achieve thyroid ablation or hypothyroidism [70, 74]. With large glands, higher doses of 131I (200–300 uCi of 131I per gm) may be needed [74].
by experienced thyroid surgeons.

Considering the intricacies of thyroidectomy in children, it is recommended that GD surgery be performed by pediatric surgeons rather than by high volume thyroid surgeons [78]. Considering the above, we believe that PTU should never be used as first line treatment in children. PTU use should only be considered in rare circumstances, such as preparation for surgery in a patient allergic to MMI or in pregnancy.

Current PTU use in children taking this medication should be stopped in favor of alternate therapies to put an end to PTU-induced liver failure in children. As such, no child with GD should experience liver injury or failure, require liver transplantation, or die due to PTU, from this time forward.

9. Conclusions

PTU was introduced for clinical use in July 1947, and MMI was introduced in June 1950. Over the six decades that PTU has been used, reports of PTU-related liver failure and death in children and adults have accumulated in published literature and FDA databases. In comparison, we are unaware of reports of death and liver failure in children and adolescents taking MMI, and there are far fewer and less serious adverse events reported for MMI than PTU in general.

Perhaps in response to concerns that have been voiced over PTU safety over the past several years [1, 4, 82], there has been a gratifying reduction in PTU use in the pediatric population over the past three years. Yet, it is likely that more than 1000 pediatric patients are still taking PTU in the United States. As such, it is estimated that at least one child will develop PTU-induced liver failure requiring transplantation over the next two years if PTU use continues at current levels.

Considering the above, we believe that PTU should never be used as first line treatment in children. PTU use should only be considered in rare circumstances, such as preparation for surgery in a patient allergic to MMI or in pregnancy.

Current PTU use in children taking this medication should be stopped in favor of alternate therapies to put an end to PTU-induced liver failure in children. As such, no child with GD should experience liver injury or failure, require liver transplantation, or die due to PTU, from this time forward.

Acknowledgments

Please note that the content is the responsibility of the authors alone and does not necessarily reflect the views or policies of the Department of Health and Human Services or other organizations. S. A. Rivkees thanks numerous colleagues for useful discussions on this subject.
Graves’ disease,” *Pediatric Transplantation*, vol. 10, no. 4, pp. 525–528, 2006.

[38] W. Khovidhunkit and R. V. Farese Jr., “Resolution of propylthiouracil-induced hepatic failure after treatment of thyrotoxicosis,” *Western Journal of Medicine*, vol. 167, no. 5, pp. 353–356, 1997.

[39] D. R. Lock and Z. M. Shoeger, “Severe hepatotoxicity on beginning propylthiouracil therapy,” *Journal of Clinical Gastroenterology*, vol. 24, no. 4, pp. 267–269, 1997.

[40] M. Waseem, K. G. Seshadri, and U. M. Kabadi, “Successful outcome with methimazole and lithium combination therapy for propylthiouracil-induced hepatotoxicity,” *Endocrine Practice*, vol. 4, no. 4, pp. 197–200, 1998.

[41] R. Deidiker and D. E. deMello, “Propylthiouracil-induced fulminant hepatitis: case report and review of the literature,” *Pediatic Pathology and Laboratory Medicine*, vol. 16, no. 5, pp. 845–852, 1996.

[42] S. Özenürler, C. Tuncer, U. Boztepe, et al., “Propylthiouracil-induced acute hepatic failure and brief literature review,” *Hepatogastroenterology*, vol. 56, no. 5, pp. 429–432, 1999.

[43] C. Huot, R. Lambert, C. Deal, R. Collu, and G. Van Vliet, “Outcome of pediatric Graves’ disease after treatment with methimazole,” *Hepatology*, vol. 30, no. 5, pp. 1236–1240, 1999.

[44] Y. T. Hung, W. K. Yu, and E. Chow, “Delayed cholestatic jaundice due to methimazole,” *Journal of Clinical Endocrinology & Metabolism*, vol. 82, no. 6, pp. 1727–1733, 1997.

[45] D. M. Arab, D. A. Malatjian, and R. S. Rittmaster, “Severe cholestatic jaundice in uncomplicated hyperthyroidism treated with methimazole,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 80, no. 4, pp. 1083–1085, 1995.

[46] N. S. Glaser and D. M. Styne, “Predicting the likelihood of Graves’ disease in children with special emphasis on radioiodine treatment,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 83, no. 11, pp. 3767–3776, 1998.

[47] J. I. Hamburger, “Management of hyperthyroidism in children and adolescents,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 60, no. 5, pp. 1019–1024, 1985.

[48] F. Kaguilidou, C. Alberti, M. Castanet, M.-A. Guitteny, P. Czersnick, and J. Léger, “Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 93, no. 10, pp. 3817–3826, 2008.

[49] B. M. Lippe, E. M. Landaw, and S. A. Kaplan, “Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 64, no. 6, pp. 1241–1245, 1987.

[50] C. Ma, A. Kuang, J. Xie, and G. Liu, “Radioiodine treatment for pediatric Graves’ disease,” *Cochrane Database of Systematic Reviews*, no. 3, Article ID CD006294, 2008.

[51] P. H. Sommuke, P. Pusuvan, S. Likitmaskul, J. Santiprabhob, and P. Sawathiparnich, “Treatment outcome of Graves’ disease in Thai children,” *Journal of the Medical Association of Thailand*, vol. 90, no. 9, pp. 1815–1820, 2007.

[52] L. Ward, C. Huot, R. Lambert, C. Deal, R. Collu, and G. Van Vliet, “Outcome of pediatric Graves’ disease after treatment with antithyroid medication and radioiodine,” *Clinical and Investigative Medicine*, vol. 22, no. 4, pp. 132–139, 1999.

[53] L. Lazar, O. Kalter-Leibovic, A. Pertzalan, N. Weintrub, Z. Josesfsberg, and M. Phillip, “Thyrotoxicosis in prepubertal children compared with pubertal and postpubertal patients,” *The Journal of Clinical Endocrinology & Metabolism*, vol. 85, no. 10, pp. 3678–3682, 2000.

[54] M. W. Russo, J. A. Galanko, R. Shrestha, M. W. Fried, and P. Watkins, “Liver transplantation for acute liver failure from drug induced liver injury in the United States,” *Liver Transplantation*, vol. 10, no. 8, pp. 1018–1023, 2004.

[55] S. A. Rivkees and D. R. Mattison, “Propylthiouracil (PTU)-induced liver failure and recommendations for the discontinuation of PTU use in children,” *International Journal of Pediatric Endocrinology*. In press.

[56] L. Wartofsky, D. Glinoer, B. Solomon, et al., “Differences and similarities in the diagnosis and treatment of Graves’ disease in Europe, Japan, and the United States..,” *Thyroid*, vol. 1, no. 2, pp. 129–135, 1991.

[57] W. C. Nicholas, R. G. Fischer, R. A. Stevenson, and J. D. Bass, “Single daily dose of methimazole compared to every 8 hours propylthiouracil in the treatment of hyperthyroidism,” *Southern Medical Journal*, vol. 88, no. 9, pp. 973–976, 1995.

[58] J. Tairaj and S. Noguchi, “Antithyroid drug-induced agranulocytosis: how has granulocyte colony-stimulating factor changed therapy?” *Thyroid*, vol. 15, no. 3, pp. 292–297, 2005.

[59] D. S. Cooper, D. Goldminz, A. A. Levin, et al., “Agranulocytosis associated with antithyroid drugs. Effects of patient age and drug dose,” *Annals of Internal Medicine*, vol. 98, no. 1, pp. 26–29, 1983.
[70] S. A. Rivkees and C. Dinauer, “Controversy in clinical endocrinology: an optimal treatment for pediatric Graves’ disease is radioiodine,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 3, pp. 797–800, 2007.

[71] J. A. Lee, M. M. Grumbach, and O. H. Clark, “Controversy in clinical endocrinology: the optimal treatment for pediatric Graves’ disease is surgery,” The Journal of Clinical Endocrinology & Metabolism, vol. 92, no. 3, pp. 801–803, 2007.

[72] G. E. Sheline, K. R. McCormack, and M. Galante, “Thyroid nodules occurring late after treatment of thyrotoxicosis with radioiodine,” The Journal of Clinical Endocrinology & Metabolism, vol. 22, pp. 8–17, 1962.

[73] B. M. Dobyns, G. E. Sheline, J. B. Workman, E. A. Tompkins, W. M. McConahey, and D. V. Becker, “Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy. Follow up study,” The Journal of Clinical Endocrinology & Metabolism, vol. 38, no. 6, pp. 976–998, 1974.

[74] S. A. Rivkees and E. A. Cornelius, “Influence of iodine-131 dose on the outcome of hyperthyroidism in children,” Pediatrics, vol. 111, no. 4, pp. 745–749, 2003.

[75] P. Miccoli, P. Vitti, T. Rago, et al., “Surgical treatment of Graves’ disease: subtotal or total thyroidectomy?” Surgery, vol. 120, no. 6, pp. 1020–1025, 1996.

[76] H. Peters, C. Fischer, U. Bogner, C. Reimers, and H. Schleusener, “Reduction in thyroid volume after radioiodine therapy of Graves’ hyperthyroidism: results of a prospective, randomized, multicentre study,” European Journal of Clinical Investigation, vol. 26, no. 1, pp. 59–63, 1996.

[77] H. Peters, C. Fischer, U. Bogner, C. Reimers, and H. Schleusener, “Treatment of Graves’ hyperthyroidism with radioiodine: results of a prospective randomized study,” Thyroid, vol. 7, no. 2, pp. 247–251, 1997.

[78] J. A. Sosa, C. T. Tuggle, T. S. Wang, et al., “Clinical and economic outcomes of thyroid and parathyroid surgery in children,” The Journal of Clinical Endocrinology & Metabolism, vol. 93, no. 8, pp. 3058–3065, 2008.

[79] P. Barbero, C. Ricagni, G. Mercado, R. Bronberg, and M. Torrado, “Choanal atresia associated with prenatal methimazole exposure: three new patients,” American Journal of Medical Genetics, vol. 129A, no. 1, pp. 83–86, 2004.

[80] P. Barbero, R. Valdez, H. Rodriguez, et al., “Choanal atresia associated with maternal hyperthyroidism treated with methimazole: a case-control study,” American Journal of Medical Genetics Part A, vol. 146A, no. 18, pp. 2390–2395, 2008.

[81] R. M. Valdez, P. M. Barbero, R. C. Liascovich, L. F. De Rosa, M. A. Aguirre, and L. G. Alba, “Methimazole embryopathy: a contribution to defining the phenotype,” Reproductive Toxicology, vol. 23, no. 2, pp. 253–255, 2007.

[82] S. A. Rivkees, “Graves’ disease therapy in children: truth and inevitable consequences,” Journal of Pediatric Endocrinology & Metabolism, vol. 20, no. 9, pp. 953–955, 2007.